查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519362

2024-2032 年按类型、药物类别、适应症、剂型、配销通路和地区分類的眼科药物市场报告

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球眼科药物市场规模达450亿美元。被诊断患有眼部疾病的人数不断增加、给药系统的重大技术进步、有利的政府倡议和资金、老年人口的增加以及患有糖尿病的人数不断增加，推动了市场的发展。

眼科药物市场分析：

主要市场驱动因素：与眼睛相关的日益严重的问题、药物配方的重大发展以及对技术和药物研究领域的强劲投资是推动眼科药物成长的一些主要市场驱动因素。

主要市场趋势：选择联合疗法的人数不断增加，产业参与者之间的策略伙伴关係不断增强，以及越来越重视为以前被认为无法治疗的疾病创造治疗方法，这些都是眼科药物市场趋势。

地理趋势：北美凭藉强大的医疗基础设施和不断增加的糖尿病相关眼部疾病诊断数量而引领市场。该行业的第二大市场是欧洲，因为该地区人口老化加剧以及研发（R&D）活动不断增加。

竞赛格局：AbbVie Inc.、Aerie Pharmaceuticals Inc.、Akorn Inc.、Alcon、Bausch Health Companies Inc.、Bayer AG、F. Hoffmann-La Roche AG、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Regeneron Pharmaceuticals Inc.、Santen Pharmaceutical Co. Ltd. 和Sun Pharmaceutical Industries Ltd 是眼科药物行业的一些主要参与者。

挑战与机会：该市场的挑战包括严格的监管环境导致药物审批延迟以及开发的眼科药物成本上升。此外，眼科药物市场近期的机会包括新兴市场的潜力，这些市场被认可的医疗保健机会不断增加。

眼科药物市场趋势：

个人眼疾患率上升

全球范围内日益增加的与眼睛相关的问题极大地增加了眼科药物的需求。根据资料，白内障、青光眼、老年黄斑部病变（AMD）和糖尿病视网膜病变等疾病正在推动市场发展。根据世界卫生组织 (WHO) 的数据，每年至少有 22 亿人有近距视力障碍。该报告还指出，至少有 10 亿个视力障碍病例本来可以避免或尚未预防。患有眼部疾病的人数不断增加，显着导致对这些治疗药物（例如抗青光眼药物、抗 VEGF 药物和抗发炎药物）的需求增加。这种相关性得到了许多市场研究报告的支持，这些报告描述了有前途的先进治疗解决方案并促进了眼科药物市场的最新开发活动。

药物输送系统的重大技术进步

可以认可新技术的药物输送系统的创新是创造积极的眼科药物市场概况的主要因素。微乳液、奈米技术或眼部植入物等新配方的可能性提供了更好的功效、安全性和患者依从性。例如，奈米级的药物载体可以显着提高药物对目标眼组织的生物利用度，从而减少频繁给药的需要以及与药物相关的任何副作用。因此，越来越多的公司正在投资这些技术，以获得市场竞争优势。业界新型眼科给药系统专利数量不断增加。上述所有研发 (R&D) 投资均以受益于新药物输送技术的细分市场的市场成长预测为基础。这意味着他们有能力显着破坏目前的眼科治疗模式。

有利的政府措施和资金

政府政策是创造积极的眼科药物市场前景的重要因素。世界各国政府推出了各种措施来改善医疗基础设施，包括让有效的眼部护理更容易获得。例如，许多国家提供了补贴眼科护理中心的开设和发展、投资研究以创造新药以及传播有关眼科疾病的信息的机会。在美国，国家眼科研究所为眼科领域的研究提供大量资金。这推动了这一领域的重大突破，为行业的良好愿景开闢了新药和机会。此外，透过 FDA 的突破性治疗指定等途径加快药物审批，可提高有远见的眼科解决方案的市场准入。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球眼科药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 处方药
    • 市场走向
    • 市场预测
  • 非处方药物
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依药物类别

  • 抗青光眼
    • 市场走向
    • 市场预测
  • 抗感染
    • 市场走向
    • 市场预测
  • 抗发炎
    • 市场走向
    • 市场预测
  • 抗过敏
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依迹象

  • 干眼症
    • 市场走向
    • 市场预测
  • 青光眼
    • 市场走向
    • 市场预测
  • 感染/发炎/过敏
    • 市场走向
    • 市场预测
  • 视网膜疾病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按剂型

  • 液体眼科药物剂型
    • 市场走向
    • 市场预测
  • 固体眼科药物剂型
    • 市场走向
    • 市场预测
  • 半固体眼科药物剂型
    • 市场走向
    • 市场预测
  • 多室给药系统
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 12 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第16章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Aerie Pharmaceuticals Inc.
    • Akorn Inc.
    • Alcon
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: SR112024A5287

The global ophthalmic drugs market size reached US$ 45.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 68.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032. The market is propelled by the rising number of individuals diagnosed with eye diseases, significant technological advancements in drug delivery systems, favorable government initiatives and funding, rising geriatric population, and increasing number of individuals suffering with diabetes.

Ophthalmic Drugs Market Analysis:

Major Market Drivers: The rising issues related to eyes, significant developments in drug formulations, and robust investment in technology and pharmaceutical research sectors are some of the major market drivers driving the ophthalmic drugs growth.

Key Market Trends: The rising number of individuals opting for combination therapies, increasing strategic partnerships among industry players, and the rising emphasis on creating treatments for conditions that were considered untreatable previously are some of the ophthalmic drugs market trends.

Geographical Trends: North America leads the market on account of a strong healthcare infrastructure and the increasing amount of diagnosis of diabetes-related eye conditions. The second largest market of the industry is Europe due to its rising aging population and increasing research and development (R&D) activities across the region.

Competitive Landscape: AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd, are among some of the key players in the ophthalmic drugs industry.

Challenges and Opportunities: Challenges of this market include the strict regulatory environments which lead to a delay in drug approvals and rising cost of developed ophthalmic drugs. Moreover, ophthalmic drugs market recent opportunities include the potential of the emerging markets accredited to the rising healthcare access.

Ophthalmic Drugs Market Trends:

Rising Prevalence of Eye Diseases Among Individuals

The increasing eye-related issues worldwide are majorly escalating the ophthalmic drugs demand. As per the data, illnesses such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are driving the market. According to the WORLD HEALTH ORGANIZATION (WHO), at least 2.2 Billion individuals each year have a near of distance vision impairment. The report also states that minimum 1 Billion of these cases of vision impairment could have been avoided or is yet to be prevented. The rising number of individuals with eye diseases are significantly leading to a rise in the demand for these therapeutic drugs such as anti-glaucoma medications, anti-VEGF agents, and anti-inflammatory agents. This correlation is supported by numerous market research reports which depict promising advanced treatment solutions and promote ophthalmic drugs market recent development activities.

Significant Technological Advancements in Drug Delivery Systems

The innovation of drug delivery systems, which can be accredited to novel technologies has been a major factor in creating a positive ophthalmic drugs market overview. New formulation possibilities such as microemulsions, nanotechnology, or ocular inserts offer better efficacy, safety, and patient adherence. For instance, drug carriers at a nano-size scale can significantly improve the bioavailability of the drug to the targeted ocular tissues, thereby reducing the need for frequent dosing and any side effects associated with the drug. As a result, more companies are investing in these technologies in order to gain a competitive edge in the market. There is a growing number of novel ophthalmic drug delivery system patents in the industry. All of the aforementioned research and development (R&D) investments are underpinned by the projections of market growth within the segments that benefit from new drug delivery technologies. This implies their ability to significantly disrupt the present ophthalmology treatment paradigm.

Favorable Government Initiatives and Funding

Government policies and act as a vital factor creating a positive ophthalmic drugs market outlook. Governments worldwide have launched various initiatives to improve healthcare infrastructure, including making effective eye care more accessible. For instance, numerous countries provide opportunities for subsidizing the opening and development of eye care centers, investing in research to create new drugs, and spreading information about eye diseases. In the United States, the National Eye Institute provides significant funding for research in the ophthalmic field. This propels a significant breakthrough in this area, opening up new drugs and opportunities in the industry for good vision. Moreover, faster drug approvals through routes such as FDA's Breakthrough Therapy designation improve market entry for visionary ophthalmic solutions.

Ophthalmic Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, drug class, indication, dosage form, and distribution channel.

Breakup by Type:

Prescription Drugs

Over-the-counter Drugs

Prescription drugs accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes prescription drugs and over-the-counter drugs. According to the report, prescription drugs represented the largest segment.

The highest ophthalmic drugs market revenue is deriving from prescription drugs. This can be accredited to the requirement of regulated forms of treatment for certain complex or severe eye disorders. Glaucoma, age-regulated macular degeneration, diabetic retinopathy, and many other conditions are typically treated with prescription medication that must be administered in precise dosages and only used through patient monitoring by a healthcare provider. Age-related macular degeneration can be categorized as dry AMD and wet AMD, and is a primary case of vision loss in individuals 50 years or older. Approximately 80% of individuals (8 out of 10) are diagnosed with dry form AMD. The rapid growth of the patient population proves the irreplaceability of prescription drugs in successful disease treatment and therapy.

Breakup by Drug Class:

Anti-glaucoma

Anti-infection

Anti-inflammation

Anti-allergy

Others

Anti-glaucoma holds the largest share in the industry

A detailed breakup and analysis of the market based on the drug class have also been provided in the report. This includes anti-glaucoma, anti-infection, anti-inflammation, anti-allergy, and others. According to the report, anti-glaucoma accounted for the largest market share.

The largest ophthalmic drugs market share is held by anti-glaucoma drugs, where glaucoma is the second leading cause of irreversible blindness globally. According to the NATIONAL INSTITUE OF HEALTH (NIH), the number of individuals suffering with glaucoma globally will rise upto 111.8 million by 2040. A rapidly growing glaucoma patient population signifies that patients need effective therapeutics on a long-term basis in order to maintain visual function, and hence there is significant demand for this segment. Additionally, drug formulation is constantly being developed to achieve maximum relief for glaucoma patients and compliance with the treatment on the part of the patient.

Breakup by Indication:

Dry Eye

Glaucoma

Infection/Inflammation/Allergy

Retinal Disorders

Others

Retinal disorders represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. According to the report, retinal disorders represented the largest segment.

Retinal disorders account for a large part of the ophthalmic drugs market, mainly due to the high frequency of diseases and their severity, which includes diabetic retinopathy and age-related macular degeneration. As per a report published by the NATIONAL INSTITUE OF HEALTH (NIH), individuals diagnosed with type 1, type 2, and gestational diabetes are more prone to diabetic retinopathy. The report also suggested that diabetic retinopathy can also lead to other serious eye conditions, such as diabetic macular edema and neovascular glaucoma. With time, approximately 1 in 15 individuals with diabetes develop DME. In the absence of treatment, these diseases often lead to complete blindness and require constant drug support, due to which the consumption of drugs in this segment is significant.

Breakup by Dosage Form:

Liquid Ophthalmic Drug Forms

Solid Ophthalmic Drug Forms

Semisolid Ophthalmic Drug Forms

Multicompartment Drug Delivery Systems

Others

Liquid ophthalmic drug forms exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the dosage form have also been provided in the report. This includes liquid ophthalmic drug forms, solid ophthalmic drug forms, semisolid ophthalmic drug forms, multicompartment drug delivery systems, and others. According to the report, liquid ophthalmic drug forms accounted for the largest market share.

On account of the need for easily administered and fast-acting medication directly into the eye, liquid ophthalmic drugs are the largest segment in the market by dosage form. Liquid dosage forms include drops, solutions, tinctures, injections, tinctures, elixirs, and syrups. Considering the relatively wide range of methods for delivering liquid medication into the eye, drops are the most prevalent, offering better controllability of dosage and higher patient adherence, thus impelling the ophthalmic drugs market growth. As per the NATIONAL INSTITUTE OF HEALTH (NIH), demand for liquid ophthalmic formulations is prominently high, with 90% of prescribed medications being eye drops. It is also driven by the introduction of non-preserved and multi-dose packaging, which increases convenience and safety. Thus, liquid formulations are widely preferred by patient and healthcare providers in cases of eye conditions.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores

Online Pharmacies

Others

Hospital pharmacies dominates the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, drug stores, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

In the market breakup by distribution channel, hospital pharmacies currently constitute the largest segment. The factor dictating this is the direct integration of these pharmacies into the healthcare facilities and immediate patient care. As a result, patients have timely access to the ophthalmic medications prescribed by their ophthalmologists. Early treatment of acute and chronic eye conditions is essential to prevent vision impairment and blindness. Hospital pharmacies, in turn, are the first to receive new drug approvals, given their affiliation with manufacturers and the purchasing power. As a result, the drug distribution and administration process are facilitated, patient adherence improves, and outcomes enhance.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest ophthalmic drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America holds the largest market share due to the developed healthcare system of the region, high healthcare expenditures, and strong presence of big pharma. Moreover, the eye disease rate in the North is high due to glaucoma, for instance, according to the NATIONAL HEALTH INSTITUE (NIH), 3 million individuals in the United States are affected by glaucoma. Another prominent reason is the sponsorship of the United States in medical research, with eye treatment gaining notable financial support.

Competitive Landscape:

The ophthalmic drugs market report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the metal fiber industry include AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Numerous major ophthalmic drugs companies are extensively involved in research and development (R&D) activities to develop new products and broaden their portfolios. For instance, in January 2023 BAUSCH HEALTH COMPANIES INC., announced the launch of PreserVision AREDS 2 Formula minigel eye vitamins in the United States. This drug acts as a therapeutic solution for individuals diagnosed with moderate-to-advanced AMD. Leading corporations such as Novartis, Roche, and Pfizer are currently working on new treatments for everything from glaucoma to age-related macular degeneration. They are also pioneering new drug delivery technologies to help medications work more effectively while still increasing patient compliance. Furthermore, these organizations have collaborated or acquired one another as part of their core business strategies, enabling them to take advantage of the other's technology capabilities and reach in different markets. The leading firms of the sector have also engaged in a large number of clinical reviews, contributing to the rapid introduction of new efficient goods.

Latest News:

February 2023: BAYER AG proposed aflibercept 8mg for regulatory approval in the EU for two major retinal illnesses.

March 2022: THEA PHARMA announced the acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. This strategic step supports the position of Thea as a major provider of products manufactured to cater to the demands of eye care specialists.

Key Questions Answered in This Report:

  • How has the global ophthalmic drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global ophthalmic drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global ophthalmic drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive ophthalmic drugs market?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the ophthalmic drugs market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the ophthalmic drugs market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the ophthalmic drugs market?
  • What is the breakup of the market based on the dosage form?
  • Which is the most attractive dosage form in the ophthalmic drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the ophthalmic drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global ophthalmic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ophthalmic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Anti-glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anti-infection
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Anti-inflammation
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Dry Eye
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Glaucoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infection/Inflammation/Allergy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Retinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Dosage Form

  • 9.1 Liquid Ophthalmic Drug Forms
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Solid Ophthalmic Drug Forms
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Semisolid Ophthalmic Drug Forms
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Multicompartment Drug Delivery Systems
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Drug Stores
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Aerie Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Akorn Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Alcon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Bausch Health Companies Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Bayer AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Regeneron Pharmaceuticals Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Santen Pharmaceutical Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Sun Pharmaceutical Industries Ltd.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Ophthalmic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Ophthalmic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Ophthalmic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Ophthalmic Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Ophthalmic Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Ophthalmic Drugs Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: Ophthalmic Drugs Market: Breakup by Dosage Form (in %), 2023
  • Figure 8: Global: Ophthalmic Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 9: Global: Ophthalmic Drugs Market: Breakup by Region (in %), 2023
  • Figure 10: Global: Ophthalmic Drugs (Prescription Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Ophthalmic Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Ophthalmic Drugs (Anti-glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Ophthalmic Drugs (Anti-glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Ophthalmic Drugs (Anti-infection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Ophthalmic Drugs (Anti-infection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Ophthalmic Drugs (Anti-inflammation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Ophthalmic Drugs (Anti-inflammation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Ophthalmic Drugs (Anti-allergy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Ophthalmic Drugs (Anti-allergy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Ophthalmic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Ophthalmic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Ophthalmic Drugs (Dry Eye) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Ophthalmic Drugs (Dry Eye) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Ophthalmic Drugs (Glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Ophthalmic Drugs (Glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Ophthalmic Drugs (Retinal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Ophthalmic Drugs (Retinal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Ophthalmic Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Ophthalmic Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Ophthalmic Drugs (Other Dosage Forms) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Ophthalmic Drugs (Other Dosage Forms) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Global: Ophthalmic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Global: Ophthalmic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Global: Ophthalmic Drugs (Drug Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Ophthalmic Drugs (Drug Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Ophthalmic Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Ophthalmic Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Global: Ophthalmic Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Global: Ophthalmic Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: North America: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: North America: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United States: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United States: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Canada: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Canada: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Asia-Pacific: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Asia-Pacific: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: China: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: China: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Japan: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Japan: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: India: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: India: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: South Korea: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: South Korea: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Australia: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Australia: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Indonesia: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Indonesia: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Europe: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Europe: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Germany: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Germany: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: France: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: France: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: United Kingdom: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: United Kingdom: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Italy: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Italy: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Spain: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Spain: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Russia: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Russia: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Latin America: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Latin America: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Brazil: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Brazil: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Mexico: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Mexico: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Others: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Middle East and Africa: Ophthalmic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 99: Middle East and Africa: Ophthalmic Drugs Market: Breakup by Country (in %), 2023
  • Figure 100: Middle East and Africa: Ophthalmic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 101: Global: Ophthalmic Drugs Industry: SWOT Analysis
  • Figure 102: Global: Ophthalmic Drugs Industry: Value Chain Analysis
  • Figure 103: Global: Ophthalmic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ophthalmic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Ophthalmic Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Ophthalmic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Ophthalmic Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: Ophthalmic Drugs Market Forecast: Breakup by Dosage Form (in Million US$), 2024-2032
  • Table 6: Global: Ophthalmic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: Ophthalmic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Ophthalmic Drugs Market: Competitive Structure
  • Table 9: Global: Ophthalmic Drugs Market: Key Players